Barclays Maintains Overweight on Iovance Biotherapeutics, Lowers Price Target to $5

Benzinga · 3d ago
Barclays analyst Peter Lawson maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and lowers the price target from $22 to $5.